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Abstract The safety of chemotherapy during pregnancy
is debatable. We present a case of advanced ovarian cancer,
diagnosed at week 28 of gestational age, treated with 2
cycles of paclitaxel/cisplatin (TC) chemotherapy during
pregnancy, with no serious toxicity. At week 34, the patient
underwent a caesarean section and delivered a healthy girl.
Four additional cycles of TC were administered. Three
months after completing chemotherapy, the patient devel-
oped abdominal progression and subsequently a huge meta-
static cystic mass in the brain. Despite subsequent
therapies, the patient died of progressive disease 35 months
after the diagnosis. The infant had normal growth and
development by 73 months of her age. This is another
reported case of ovarian cancer diagnosed during the sec-
ond trimester of the pregnancy treated with TC chemother-
apy without apparent teratogenic eVect.
Keywords Pregnancy · Ovarian carcinoma · 
Chemotherapy
Introduction
Diagnosis of cancer during pregnancy is uncommon, with
breast and cervical cancer, lymphoma, and melanoma being
the most frequent malignancies. Nevertheless, the inci-
dence of cancer in pregnancy is increasing, probably due to
routine use of sonography during prenatal care and the ten-
dency to postpone childbirth to an older age. The standard
therapy for advanced epithelial ovarian cancer (EOC) con-
sists of cytoreductive surgery followed by chemotherapy,
preferably including paclitaxel combined with cisplatin or
carboplatin. We present here a case of a pregnant woman
with advanced EOC, treated with paclitaxel/cisplatin (TC)
chemotherapy, with preservation of the pregnancy.
A case
A 24-year-old woman, gravida 1, presented with an asymp-
tomatic polycystic adnexal mass diagnosed at week 28 of
gestation at the routine ultrasound examination. The patient
had no history of ovarian, colon or breast cancer in the fam-
ily. She underwent a laparotomy with bilateral salpingo-
oophorectomy, omentectomy and appendectomy. Intraop-
erative examination showed disseminated small multiple
peritoneal nodules and a few superWcial liver metastases up
to 2 cm in size. The postoperative course was uneventful.
The abdomen ultrasound performed postoperatively con-
Wrmed the presence of metastatic liver lesions sized 32–
80 mm, located in both lobes. The Wnal diagnosis was stage
IV, grade 2 mucinous ovarian adenocarcinoma. After
extensive discussion with the patient and her family,
informed consent was obtained for postoperative chemo-
therapy, with attempted preservation of the pregnancy.
Nineteen days after the surgery, chemotherapy consisting
of paclitaxel 175 mg/m2 over 3 h and cisplatin 75 mg/m2,
with standard premedication of steroids and anti-emetics
(20 mg dexamethason twice a day, 8 mg ondansetrone) was
initiated. The baseline serum liver and renal function tests
were normal; the level of Ca 125 before starting chemother-
apy was 71 IU/ml. After 3 weeks, the patient received a
second chemotherapy cycle. Treatment was well tolerated.
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At week 34, after administration of corticosteroids for foe-
tal lung maturation, a caesarean section with staging lapa-
rotomy was performed. The exploration of the abdomen
cavity showed multiple small persisted post-chemotherapy
lesions located in the perimetrium, peritoneum of vesicou-
terine fold, Douglas sinus and the diaphragmatic dome, as
well as metastatic lesions on the liver surface of 0.1–1 cm
in diameter. The woman delivered a healthy girl (1,900 g,
Apgar score 8 at 5 min, and normal laboratory tests). There
were no peri- or postoperative complications. Four addi-
tional TC cycles were administered. Ca 125 level after
completing the sixth cycle of chemotherapy was 39 IU/ml.
Progressive disease in the liver (tumour lesions of
55 £ 46 mm in size) and enlarged para-aortic lymph nodes
were found on CT scans performed 3 months later. Subse-
quent 7 cycles of topotecan resulted in disease stabilization
and Ca 125 level was 30 IU/ml. Topotecan administration
was stopped after a huge cystic mass (55 £ 45 £ 50 mm)
in the brain had been diagnosed, following headache com-
plaints. Negative cytology was obtained after diagnostic
biopsy. The patient received palliative whole brain irradia-
tion of 20 Gy in 5 fractions followed by chemotherapy:
subsequently single-agent carboplatin, cyclophosphamide/
cisplatin and Wnally 2 cycles of liposomal doxorubicin.
Despite therapy, 35 months after cancer diagnosis, the
patient died of progressive abdominal lesions without cen-
tral nervous system symptoms. The infant had normal
growth and development at 73 months of her age.
Discussion
The development of malignant disease during pregnancy
leads to an enormous emotional burden to the patient, her
partner and the medical staV, accompanied by medical
dilemmas. Surgery for malignant tumours seems to be safe,
whereas the teratogenicity of cytotoxic agents depends on
several factors, including their type, timing of exposure,
dose and characteristics aVecting placental transfer [1]. The
use of chemotherapy during the Wrst trimester increases the
risk of spontaneous abortion, foetal death and major malfor-
mation and is generally contraindicated in this period. Accu-
mulating data suggests that at the time organogenesis is
completed, the risk of intrauterine growth restriction and
low birth-weight is low. In consequence, chemotherapy is a
viable option in selected pregnant women. However, only a
few studies have evaluated the long-term consequences for
children exposed to chemotherapy while in utero [1–5].
Owing to the limited clinical experience and the unique tax-
ane antineoplastic mode of action, generally the use of tax-
anes in pregnancy is not recommended [1]. Until now, only
a few cases of chemotherapy with taxanes, including paclit-
axel alone or in combination with either cisplatin or carbo-
platin, applied during pregnancy, have been reported [1, 3,
4, 6–14]. In all cases but one, organogenesis had been com-
pleted by the time of treatment onset. Current experience
includes Wve cases of EOC treated with 6, 5 (two cases), 4
and 3 cycles of paclitaxel-based chemotherapy, respectively,
and one patient with FIGO III dysgerminoma administered
4 cycles of paclitaxel/carboplatin (Table 1) [6, 9–12, 14].
We presented another patient with advanced EOC, who
received 2 cycles of TC chemotherapy during the second tri-
mester of pregnancy. Therapy did not apparently aVect the
development of the infant during the Wrst 6 years of observa-
tion. No teratogenic eVects of 3 cycles of TC combination
(with paclitaxel administered at 135 mg/m2/24 h) for EOC
during pregnancy were reported by Sood et al. [14] in 2001.
Similarly to our case, the patient’s outcome was fatal,
whereas the growth and the development of the infant was
normal at 29 months of age. No teratogenic eVect was also
shown within 20 months of the infant’s life in the dysgermi-
noma patient administered paclitaxel/carboplatin chemo-
therapy [9]. In another case, the episode of respiratory
insuYciency occurring immediately after the delivery in a
newborn exposed to 3 cycles of TC chemotherapy due to
mother’s lung cancer was considered to be related to neona-
tal prematurity rather than chemotherapy toxicity [7].
Overall, there have been so far about 52 reports of preg-
nant women managed with platinum-based chemotherapy,
including 19 women treated for EOC with 2–6 cycles of
single-agent or cisplatin/carboplatin-containing multidrug
chemotherapy, starting at the second or third trimester of
gestation [3–6, 10–17].
Our patient was administered cisplatin as it is preferred
over carboplatin owing to the higher risk of thrombocyto-
penia [1]. Additionally, in 2004 at the start of chemother-
apy, the clinical experience on the use of carboplatin
treatment in pregnant women was very limited.
The review of all studies (published in English from
1977 to March 2008) concerning platinum therapy showed
43 cases of pregnant women (cisplatin in 36, carboplatin in
6, and both agents in one patient) [5]. In this group two foe-
tal malformations were recorded, in both cases after therapy
with cisplatin. However, causality related to in utero cis-
platin exposure could not be proven. Acute respiratory dis-
tress (in three premature newborns), cytopenia, elevation of
serum creatinine and hearing impairment were also
observed. No foetal malformations and normal neonatal
examinations were reported after therapy with carboplatin.
It is believed that the administration of both platinum salts
is feasible during the second and third trimester of preg-
nancy; however owing to the transplacental transfer of
these drugs in late pregnancy, collecting further data on ter-
atogenic eVects remains highly relevant.
Until now, the longest reported follow-up of the children
exposed to intra-uterine chemotherapy with cisplatin orArch Gynecol Obstet (2011) 283 (Suppl 1):S97–S100 S99
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paclitaxel, with no evidence of sequelae, has been
42 months and 40 months, respectively [6, 15]. We have
reported another case of a child exposed to the TC combi-
nation with no evidence of sequelae after 73 months of fol-
low-up.
The staging and treatment of cancer at pregnancy should
preferentially follow the standard approach [2]. Due to
increased levels of Ca 125 in pregnancy and puerperium,
the diagnostic value of this assay is limited [18]. The typi-
cal management of ovarian carcinoma includes total hyster-
ectomy. Pregnant women diagnosed with advanced EOC
should undergo organ-saving surgery, with the removal of
the reproductive organs only after the delivery [19]. In our
case, the surgery was restricted to a mere staging and this
might have worsened treatment eYcacy.
The prognosis of maternal ovarian cancers is similar to
those in non-pregnant women in the reproductive age [20].
Suboptimal therapy and initial advanced stage of disease as
a result of delayed diagnosis in some pregnant women are
associated with worse outcome. The presented case was
diagnosed in an advanced stage, with no real chance for
cure.
In conclusion, standard chemotherapy including paclit-
axel for advanced EOC diagnosed during pregnancy seems
to be safe; however, potential risks and beneWts of this ther-
apy still have to be cautiously weighted.
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